New pill could free patients from Long-Term steroid use for painful muscle condition

NCT ID NCT07279688

Summary

This study is testing if adding a pill called baricitinib to standard steroid treatment helps people with polymyalgia rheumatica (PMR) better control their disease and use steroids for a shorter time. It will involve 140 adults in France who have newly diagnosed or treatment-resistant PMR. The main goal is to see if patients can achieve low disease activity without needing steroids after 24 weeks of treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POLYMYALGIA RHEUMATICA (PMR) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • APHP - Kremlin-Bicêtre

    Le Kremlin-Bicêtre, 94270, France

    Contact Email: •••••@•••••

  • Besançon-CIC

    Besançon, 25000, France

    Contact Email: •••••@•••••

  • CARVAJAL ALEGRIA Guillermo

    Tours, France

    Contact Email: •••••@•••••

  • CHU Reims

    Reims, France

    Contact Email: •••••@•••••

  • CHU de Bordeaux Pellegrin

    Bordeaux, 33076, France

    Contact Email: •••••@•••••

  • CHU de Nice

    Nice, 06000, France

    Contact Email: •••••@•••••

  • CHU de Toulouse

    Toulouse, 31059, France

    Contact Email: •••••@•••••

  • DIREZ Guillaume

    Le Mans, France

    Contact Email: •••••@•••••

  • Dr Alain SARAUX

    Brest, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • FAUTREL Bruno - AP-HP La Pitié-Salpétrière

    Paris, France

    Contact Email: •••••@•••••

  • FLIPO René-Marc

    Lille, France

    Contact Email: •••••@•••••

  • GOTTENBERG Jacques-Eric

    Strasbourg, France

    Contact Email: •••••@•••••

  • LE HENAFF Catherine

    Morlaix, France

    Contact Email: •••••@•••••

  • LEGRAND Jean-Louis

    Arras, France

    Contact Email: •••••@•••••

  • LESKE Charles

    Cholet, France

    Contact Email: •••••@•••••

  • OTTAVIANI Sébastien - AP-HP Bichat

    Paris, France

    Contact Email: •••••@•••••

  • PRATI Clément

    Besançon, France

    Contact Email: •••••@•••••

  • RAMON André

    Dijon, France

    Contact Email: •••••@•••••

  • RAT Anne-Christine

    Caen, France

    Contact Email: •••••@•••••

  • TOURNADRE Anne

    Clermont-Ferrand, France

    Contact Email: •••••@•••••

  • VIDAL François

    Aix-en-Provence, France

    Contact Email: •••••@•••••

  • WIRTH Théo

    Marseille, France

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.